Eterna Therapeutics
ERNA
15 hedge funds and large institutions have $711K invested in Eterna Therapeutics in 2026 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.
125% more first-time investments, than exits
New positions opened: 9 | Existing positions closed: 4
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
36% more funds holding
Funds holding: 11 → 15 (+4)
0% more ownership
Funds ownership: 0.49% → 0.49% (+0%)
38% less capital invested
Capital invested by funds: $1.15M → $711K (-$441K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BL
Bleichroeder LP
New York
|
+$1.28M |
| 2 |
DIG
Dauntless Investment Group
Etna,
New Hampshire
|
+$391K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$141K |
| 4 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$34.7K |
| 5 |
WAM
Warberg Asset Management
Winnetka,
Illinois
|
+$31.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Corient Private Wealth
Miami,
Florida
|
-$280K |
| 2 |
HF
HRT Financial
New York
|
-$15K |
| 3 |
FFO
Fortitude Family Office
Scottsdale,
Arizona
|
-$965 |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$41 |
| 5 |
Morgan Stanley
New York
|
-$36 |
ERNA Hedge Fund Activity: Q1 2026 in Review
15 of the 8,128 institutional investors tracked by Wall St. Rank reported a position in Eterna Therapeutics (ERNA) for Q1 2026, worth a combined $711K — down 38% from $1.15M a quarter earlier.
Buyers outnumbered sellers: 9 funds opened new ERNA positions and 4 closed out — a net gain of 5 holders — while 2 added to existing stakes and 1 trimmed.
The largest buyer was Bleichroeder LP, opening a new position worth an estimated $1.28M. The largest seller was Corient Private Wealth, cutting an estimated $280K.
- 15 institutional investors held Eterna Therapeutics (ERNA) as of Q1 2026, up from 11 in Q4 2025.
- Funds reported $711K of Eterna Therapeutics stock for Q1 2026, down 38% quarter-over-quarter.
- 9 funds opened new Eterna Therapeutics positions in Q1 2026 and 4 closed out, a net change of +5 holders.
- The largest Eterna Therapeutics buyer in Q1 2026 was Bleichroeder LP, an estimated $1.28M added.
- The largest Eterna Therapeutics seller in Q1 2026 was Corient Private Wealth, an estimated $280K sold.
Based on aggregated 13F filings for Q1 2026.